Online on 12 August, the editorial written by Eleni Armeni, Antonio Cano, Margaret Rees, and Irene Lambrinoudaki after the publication of the 20-year WHI follow-up data concludes that estrogen monotherapy is safe in the long-term with regard to breast cancer risk.
The need to use progestogens with a better breast safety profile, such as micronized progesterone or dydrogesterone becomes even more evident.
Menopausal Hormone Therapy and breast cancer risk: Individualization is the key to safety
powered by Borlabs Cookie